Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.912,10
-0,30%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kezar Life Sciences Inc (KZR) Kezar Life Sciences Inc (KZR) Notizie

KZR

Kezar Life Sciences (KZR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZR
DataOraFonteTitoloSimboloCompagnia
03/12/202422:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
12/11/202422:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
12/11/202422:01Business WireKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
29/10/202422:05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:KZRKezar Life Sciences Inc
28/10/202413:30Business WireKezar Life Sciences Announces 1-for-10 Reverse Stock SplitNASDAQ:KZRKezar Life Sciences Inc
17/10/202415:22Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:KZRKezar Life Sciences Inc
17/10/202414:35Business WireKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanNASDAQ:KZRKezar Life Sciences Inc
17/10/202414:30Business WireKezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE UpdateNASDAQ:KZRKezar Life Sciences Inc
10/10/202414:30Business WireKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalNASDAQ:KZRKezar Life Sciences Inc
04/10/202423:00Business WireKezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
30/09/202414:30Business WireKezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis PatientsNASDAQ:KZRKezar Life Sciences Inc
04/09/202422:01Business WireKezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/08/202422:02Business WireKezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
26/07/202423:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
10/07/202422:01Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
29/05/202422:01Business WireKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
09/05/202422:01Business WireKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
06/05/202422:05Business WireKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
14/03/202421:01Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
28/02/202422:01Business WireKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:KZRKezar Life Sciences Inc
27/02/202400:30Business WireEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
14/02/202412:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KZRKezar Life Sciences Inc
17/01/202423:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
21/11/202322:01Business WireKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/11/202322:01Business WireKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
03/10/202322:10Business WireKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerNASDAQ:KZRKezar Life Sciences Inc
21/09/202302:30Dow Jones NewsStocks to Watch: FedEx, Kezar Life Sciences, TranscatNASDAQ:KZRKezar Life Sciences Inc
21/09/202300:30Business WireKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaNASDAQ:KZRKezar Life Sciences Inc
31/08/202322:01Business WireKezar Life Sciences to Participate in Three Upcoming Investor ConferencesNASDAQ:KZRKezar Life Sciences Inc
10/08/202322:01Business WireKezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZR

La tua Cronologia

LSE
0A4C
Altimmune
AQSE
SKYU.GB
First Trust Cloud Comput...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network